Biotech Values

[jq1234]

While the sample chosen certainly might not be representative of whole population, the gist of it is not surprising to me. It was pretty much my concern how real world patients would do after seeing the label and FDA review document. It would be better to figure out early in launch, do dose titration and dose reduction type strategy, I doubt it would affect efficacy that much, so it isn't fatal at all.